Benefit-risk evaluation of ziv-aflibercept in combination with irinotecan-fluoropyrimidine-based chemotherapy (FOLFIRI) from the VELOUR trial using multicriteria decision analysis (MCDA).
Teresa Macarulla
No relevant relationships to disclose
Jasmanda Wu
Employment or Leadership Position - Sanofi
Larry Phillips
No relevant relationships to disclose
Sheikh Usman Iqbal
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Chris Kripas
Employment or Leadership Position - Sanofi
Zheng Gu
Employment or Leadership Position - Sanofi
Amy Freedman
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Pankaj Bhargava
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Eric Van Cutsem
Research Funding - Sanofi